Press Release Source: ImmuCell Corporation On Thursday June 9, 2011, 8:00 am EDT
PORTLAND, ME--(Marketwire - 06/09/11) - ImmuCell Corporation (NASDAQ:ICCC - News) today announced that the Center for Veterinary Medicine, U.S. Food and Drug Administration (FDA) has accepted the pivotal Nisin residue data in milk and has assigned a zero milk discard time and zero meat withdrawal period. These 'claims' are subject to obtaining the Human Food Safety (HFS) Technical Section Complete Letter and ultimately approval of the New Animal Drug Application (NADA).
Mast Out® is an intramammary treatment for subclinical mastitis in lactating dairy cattle. The remaining element of the HFS Technical Section is the submission to and acceptance by the FDA of ImmuCell's Nisin residue method in milk to measure Nisin concentrations around the newly assigned tolerance limit.
'Zero Discard' means that there would be no requirement to discard milk during treatment or for a period of time thereafter. ImmuCell management believes that this would be a significant competitive advantage differentiating Mast Out® from all other intramammary antibiotics. Market acceptance of this novel product, as a tool capable of revolutionizing the way that mastitis is treated, is critically dependent upon achieving this zero milk discard claim.
"The ruling -- second in importance only to effectiveness -- provides renewed impetus to achieve approval as quickly as possible," commented Dr. Joseph H. Crabb, Vice President and Chief Scientific Officer.
Currently, the FDA is taking a closer look at antibiotic residues in all food products, while global markets are demanding milk products with lower somatic cell counts, indicative of infection status. This market environment may be favorable to the launch of a product like Mast Out®.
About ImmuCell:
ImmuCell Corporation's (NASDAQ:ICCC - News) purpose is to create scientifically-proven and practical products that result in a measurable economic impact on animal health and productivity in the dairy and beef industries. Press releases and other information about the Company are available at our web-site, (http://www.immucell.com).
Recent ICCC News
- Form SCHEDULE 13D/A - General Statement of Acquisition of Beneficial Ownership: [Amend] • Edgar (US Regulatory) • 09/17/2024 05:49:10 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 08/30/2024 04:25:45 PM
- Form SC 13D - General Statement of Acquisition of Beneficial Ownership • Edgar (US Regulatory) • 08/27/2024 08:32:59 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 08/26/2024 07:00:37 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 08/22/2024 05:05:58 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 08/19/2024 05:04:06 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 08/13/2024 08:05:51 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 08/13/2024 08:05:29 PM
- ImmuCell Announces Unaudited Financial Results for the Quarter Ended June 30, 2024 • GlobeNewswire Inc. • 08/13/2024 08:05:00 PM
- ImmuCell to Announce Unaudited Financial Results for the Quarter Ended June 30, 2024 • GlobeNewswire Inc. • 08/07/2024 08:05:52 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 07/09/2024 08:05:09 PM
- ImmuCell Announces Preliminary, Unaudited Sales Results for Q2 2024 • GlobeNewswire Inc. • 07/09/2024 08:05:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 06/14/2024 05:38:21 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 06/14/2024 03:33:12 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 06/06/2024 11:49:43 AM
- ImmuCell Provides Update on Regulatory Status of Product Development Initiative for Re-Tain® • GlobeNewswire Inc. • 06/05/2024 08:05:00 PM
- ImmuCell to Hold Virtual-Only Annual Meeting of Stockholders • GlobeNewswire Inc. • 06/04/2024 08:05:00 PM
- Form SCHEDULE 13D - General statement of acquisition of beneficial ownership • Edgar (US Regulatory) • 05/22/2024 08:50:57 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 05/14/2024 08:06:15 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 05/14/2024 08:05:51 PM
- ImmuCell Announces Unaudited Financial Results for the Quarter Ended March 31, 2024 • GlobeNewswire Inc. • 05/14/2024 08:05:00 PM
- ImmuCell to Announce Unaudited Financial Results for the Quarter Ended March 31, 2024 • GlobeNewswire Inc. • 05/08/2024 05:00:48 PM
- ImmuCell Announces Preliminary, Unaudited Sales Results for Q1 2024 • GlobeNewswire Inc. • 04/09/2024 08:05:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 03/06/2024 06:55:31 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/27/2024 09:05:32 PM
VHAI - Vocodia Partners with Leading Political Super PACs to Revolutionize Fundraising Efforts • VHAI • Sep 19, 2024 11:48 AM
Dear Cashmere Group Holding Co. AKA Swifty Global Signs Binding Letter of Intent to be Acquired by Signing Day Sports • DRCR • Sep 19, 2024 10:26 AM
HealthLynked Launches Virtual Urgent Care Through Partnership with Lyric Health. • HLYK • Sep 19, 2024 8:00 AM
Element79 Gold Corp. Appoints Kevin Arias as Advisor to the Board of Directors, Strengthening Strategic Leadership • ELMGF • Sep 18, 2024 10:29 AM
Mawson Finland Limited Further Expands the Known Mineralized Zones at Rajapalot: Palokas step-out drills 7 metres @ 9.1 g/t gold & 706 ppm cobalt • MFL • Sep 17, 2024 9:02 AM
PickleJar Announces Integration With OptCulture to Deliver Holistic Fan Experiences at Venue Point of Sale • PKLE • Sep 17, 2024 8:00 AM